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Summary
Glasgow Prognostic Score (GPS) is such an infl ammation-based factor, defi ned by the combination of the level of 
 serum C-reactive protein (CRP) and albumin, which are indicators of systematic infl ammatory response and nutritional 
status. A higher score is associated with a worse prognosis of diff erent tumor sites. The score is based on the immunomodu-
latory and infl ammatory status found in patients with elevated CRP. We hypothesized that there is a correlation between 
GPS and histopathological tumor characteristics and GPS and perioperative administration of erythrocyte concentrates in 
patients undergoing curative tumor resection. We retrospectively revied the data of fi fty-one consecutive patient who 
 underwent elective colorectal surgery. We extracted the values of preoperative C-reactive protein(CRP) and albumin and 
calculated the GPS. We correlated the histopathology of cancer and perioperative transfusion with the outcome. GPS 0 and 
2 having a tumor localized in the colon, with GPS 1 in the rectum. T4 tumor stage had patients only in the group of GPS 2 
which was statistically signifi cant from the GPS 0 group. The GPS was not associated with the presence of metastases in the 
lymph nodes, lymphatic and perineural invasions, while a statistically signifi cant diff erence was present comparing GPS 
with tumor deposits between GPS 0 and GPS 1 and GPS 0 and GPS 2. Transfusions were statistically signifi cantly higher in 
GPS 2 group compared to GPS 0 and 1. A higher GPS score is associated with the changes of immune status of the tumor 
environment which can aff ect the recurrence of the disease and survival. GPS should be considered when recommending 
the frequency of follow up and therapy after curative tumor resection. We have shown that there is an increased risk for 
perioperative blood consumption, which may independently result in a worse prognosis of the underlying disease.
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POVEZANOST UPALNOG STATUSA, PATOHISTOLOŠKIH KARAKTERISTIKA I PERIOPERATIVNE POTREBE 
ZA TRANSFUZIJSKIM LIJEČENJEM U BOLESNIKA S KOLOREKTALNIM KARCINOMOM
Sažetak
Prognostički upalni zbroj (Glasgow prognostic score, GPS) omogućava prognozu ishoda bolesti u osoba s rakom. 
 Baziran je na serumskim biomarkerima C-reactivnom proteinu (CRP) i albuminu. Viši zbroj povezan je s lošijom prognozom 
bolesti. Mehanizam se temelji na imunomodulaciji i upalnom miljeu bolesnika s povišenim CRP-om. Resekcija debelog 
 crijeva izvršena je u 51 bolesnika. CRP i albumini određeni su prije operacije. GPS je uspoređen s patohistološkim karakte-
ristikama tumora i perioperacijskom transfuzijom koncentrata eritrocita. Utvrđeno je statistički značajna razlika u sijelu 
tumora analiziranih skupina.Značjano veći broj bolesnika s GPS 0 i 2 imao je tumor lokaliziran u kolonu, a s GPS 1 u rektu-
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mu. Tumorski stadij T4 imali su bolesnici samo u skupini GPS 2 što je statistički značajno različito od skupine GPS 0. GPS 
nije bio povezan s prisutnošću metastaza u limfne čvorove, limfatične i perineuralne invazije, dok je statistički značajna 
 razlika bila u prisutnosti tumorskih depozita između GPS 0 i GPS 1, te GPS 0 i GPS 2. Statistički značajno češće krv je 
 transfudirana bolesnicima GPS 2 skupine u odnosu na GPS 0 i 1. GPS je povezan s patohistološkim karakteristikama, povra-
tom bolesti, preživljenjem i većim rizikom za primjenu krvi.
KLJUČNE RIJEČI: Glasgow prognostički zbroj, kolorektalni karcinom, tumorski depozit, transfuzija krvi
INTRODUCTION
The infl ammatory response and malnutri-
tion, perioperative treatment with blood products 
infl uence colorectal cancer prognosis. Infl amma-
tory factors and malnutrition are components of 
Glasgow Prognostic Score (GPS): serum level of 
C-reactive protein (CRP) and serum albumin con-
centration. The higher scores associated with, the 
worse prognosis (1,2). When the cancer cells stim-
ulate the infl ammatory response, the cytokine lev-
els increase and the phenotype of the immune 
cells changes. Consequently, promotion of angio-
genesis and inhibition of apoptosis and DNA 
damage and thus increases the malignant poten-
tial of cancer cells(3,4,5). In this study, we hypoth-
esized that there is a correlation of preoperative 
GPS value with histopathological characteristics 
of the colorectal tumor after curative surgical pro-
cedures. Likewise, we looked at the correlation of 
preoperative GPS with perioperative complica-
tions measured by higher blood loss (more than 
one dose of erythrocyte concentrate).
PATIENTS AND METHODS
At University Hospital for Tumors from 2014 
to 2015, we retrospectively selected fi fty-one pa-
tients with colorectal carcinomas surgically treat-
ed with curative intent. The age of patients ranged 
from 38 to 82 years, mean 65.1; 33 male and 18 fe-
male patients. We did not include patients with 
chronic infl ammation in their history and neoad-
juvant chemotherapy.
The blood samples were collected in tubes 
without anticoagulant immediately before sur-
gery, and CRP and albumin analyzed. CRP and 
albumin were measured from serum obtained by 
centrifuging whole blood at 3500 rpm for 10min. 
CRP and albumin tests were performed on auto-
matic analyzer COBAS INTEGRA 400 plus manu-
factured by Roche using C-Reactive Protein (La-
tex) reagent (CRPLX) and Albumin Gen.2 reagent 
(ALB2) from the same manufacturer. CRP mea-
suring is based on the particle-enhanced turbidi-
metric assay. Human CRP agglutinates with latex 
particles coated with monoclonal anti-CRP anti-
bodies. The precipitate is determined turbidimet-
rically at 552 nm. Albumin concentration was 
measured by colorimetric assay with endpoint 
method. At a pH of 4.1 albumin displays a suffi  -
ciently cationic character to be able to bind with 
bromcresol green (BCG), an anionic dye, to form a 
blue-green complex. The color intensity of the 
blue-green color is directly proportional to the al-
bumin concentration in the sample. It is deter-
mined by monitoring the increase in absorbance 
at 583 nm. COBAS INTEGRA automatically calcu-
lates the analyte concentration of each sample (6). 
Blood consumption data were collected from the 
transfusion program, Delfi n. Histopathological 
characteristics were obtained from the hospital 
system after surgery. Patients with CRP >10 mg/L 
and albumin <35 g/L were classifi ed in the GPS 2 
group, only elevated CRP or lowered albumin 
level were classifi ed into GPS 1 group and patients 
who did not have any of the characteristics in GPS 
0. Al statistical analysis was performed using 
MedCalc Version 18.11. The Chi-square test was 
used to determine statistically signifi cant diff er-
ences between histopathological parameters ex-
pressed in percentages between three groups of 
GPS 0, 1 and 2 and the diff erences between the 
percentage of patients who received erythrocyte 
concentrations in these groups. P<0,05 was con-
sidered signifi cant.
RESULTS
The table shows the distribution of patients 
depending on the GPS and the histopathological 
characteristics of the tumor for each group. P1 rep-
resents the diff erence between GPS 0 and GPS 1 
groups, p2 between GPS 1 and GPS 2 groups and 
p3 between GPS 0 and GPS 2 groups. Statistically 
signifi cant diff erences were found in tumor posi-
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tion between analyzed groups, with a higher num-
ber of patients with GPS 0 and 2 having a tumor 
localized in the colon, GPS 1 in the rectum. Stage T4 
was found in the group with GPS 2 which was sig-
nifi cantly diff erent from the GPS 0 group. For me-
tastases in the lymph nodes, the lymphatic and 
perineural invasion there was no diff erence be-
tween the three groups, while a statistically signifi -
cant diff erence was observed in the presence of tu-
mor deposits between GPS 0 and GPS 1 and GPS 0 
and GPS 2. Statistically signifi cant more blood was 
transfused to the patients of the GPS2 group com-
pared to GPS 0 and 1.Transfusions were higher in 
GPS2 group compared to GPS 0 and 1.
DISCUSSION
Glasgow prognostic score (GPS), is a combi-
nation of serum CRP and albumin levels, an in-
fl ammatory score which assesses the malignant 
potential of diff erent cancers. GPS is used as a 
prognostic factor for various gastrointestinal tu-
mors (7,8) but was fi rst descibed for lung cancer in 
2003.(9). Malignant potential is determined pri-
marily by histopathological characteristics but 
should include other modifi ers such as GPS.
We demonstrated the correlation between 
preoperative infl ammatory and nutritional status 
in patients with histopathological tumor charac-
teristics and their infl uence on postoperative com-
plications such as blood loss and transfusion 
needs. Given the statistically signifi cant diff erence 
between the groups in the presence of tumor de-
posits, we suggest that GPS might be a signifi cant 
indicator of possible distant metastases and poor 
prognosis, regardless of other characteristics such 
as lymphatic, perineural and lymphovascular in-
vasion. The existence of tumor deposits correlates 
with a worse prognosis for lower disease stages 
(10). Higher GPS correlates with the incidence of 
distant metastases for T1 and T2 cancers (11). In-
creased level of preoperative CRP correlates with 
T lymphocyte immunomodulation and low infi l-
tration of T lymphocytes into tumor., which may 
Table 1.












(%) p1 p2 p3
All 51 25 24
Colon 19 5 10 73 38 83 0,02 0,02 0,46
Rectum 7 8 2 27 62 17 0,02 0,01 0,45
Depth of tumor
T1 8 2 0 30 15 0 0,21 0,22 0,03
T2 3 5 2 12 38 16 0,07 0,19 0,88
T3 15 6 9 58 47 75 0,71 0,28 0,38
T4 1 9 0,05 0,17 0,05
Nodal metastasis
No 11 7 9 42 54 75 0,76 0,28 0,12
Yes 15 6 3 58 46 25 0,73 0,28 0,12
Lyphatic invasion
No 21 11 9 81 85 75 0,63 0,33 0,5
Yes 5 2 3 19 15 25 0,63 0,33 0,5
Perineural invasion
No 26 13 12 100 100 100
Yes 0 0 0 0 0 0
Tumor deposits
Yes 8 11 12 31 85 100 0,001 0,24 0,001
No 18 2 0 69 15 0 0,001 0,22 0,0001
Perioperative 
transfusion 10 3 9 38 25 75 0,44 0,02 0,05
GPS, Glasgow prognostic score; lelels of statistical signifi cance obtained by comparison of two groups p1 (GPS0 vs. GPS1), p2 (GPS1 vs. GPS2), p3 (GPS0 vs. GPS2).
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trigger tumor progression in patients undergoing 
curative colorectal resection (12,13). The mecha-
nism of immunomodulation probably presented 
here is similar to ones described for immunomod-
ulation induced by transfusions (14). We have 
shown that transfusion is more common in pa-
tients with hypoalbuminemia and elevated CRP 
compared to patients who had a single factor or 
none. Some studies show that preoperative ane-
mia correlates with right-sided tumors, greater 
depth of tumor invasion, use of neoadjuvant che-
motherapy, poor prognostic nutritional index and 
higher modifi ed Glasgow Prognostic Score 
(mGPS). The microcytic anemia, in particular, is 
strongly associated with the greater depth of tu-
mor invasion (P = 0.0072) and higher mGPS (P = 
0.0058) than other causes of anemia. Perioperative 
blood transfusion for CRC patients with anemia 
correlates with adverse outcomes (15). Hypoalbu-
minemia is also a risk factor for perioperative 
transfusion and survival of patients who had a 
liver resection (16).
CONCLUSION
Combination of changes in infl ammatory sta-
tus and perioperative blood application may in-
fl uence the poor prognosis of the disease and re-
ferral to other types of treatment after the curative 
operation, regardless of the histopathological sta-
tus of the tumor itself. However, extensive pro-
spective research is needed on a more signifi cant 
number of patients and fi ve years follow up to de-
termine the actual impact on the survival and re-
currence of the disease.
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